(S)-Tert-Butyl 2-(5-Iodo-1H-Imidazol-2-Yl)Pyrrolidine-1-Carboxylate

At a molecular weight of 363.2 g·mol⁻¹ and with a defined (S)-configuration at the pyrrolidine 2-position, the tert-butyloxycarbonyl-protected 5-iodoimidazole derivative functions as a non-racemic electrophilic building block in fragment-based drug synthesis. The imidazole iodine atom is activated toward oxidative addition with palladium(0) species, while the Boc-carbamate preserves secondary amine nucleophilicity until deprotection is triggered under strictly anhydrous acidic conditions. Every batch released from kilogram-scale campaigns is accompanied by a certificate of analysis that reports specific optical rotation [α]^20_D −48° to −52° (c 1.0, CHCl₃), chiral HPLC enantiomeric excess >99.0%, and residual palladium below 10 ppm by ICP-MS per ICH Q3D risk assessment. Laboratory-scale process development records confirm that the iodoimidazole ring is incompatible with prolonged exposure to strong bases at temperatures exceeding 40 °C, which can induce imidazole ring halogen displacement and pyrrolidine racemisation through enolate formation. Consequently, cross-coupling protocols have been optimised to operate in near-neutral pH windows, with reaction progress monitored by inline ReactIR tracking of the 2150–2250 cm⁻¹ alkyne stretch in Sonogashira modifications or by HPLC area-percent disappearance of the starting iodide peak at RRT 1.00. The downstream synthetic routes described below are drawn from actual kilo-lab and pilot-plant campaigns where this compound was utilised to construct advanced pharmaceutical intermediates intended for regulatory starting-material designation.

In a typical Sonogashira-type alkynylation sequence executed in a 50 L glass-lined reactor equipped with a retreat-curve impeller and nitrogen-sparging dip tube, 1.00 eq of the iodoimidazole-pyrrolidine is combined with 1.15 eq of a substituted phenylacetylene, 2.0 mol% Pd(PPh₃)₂Cl₂, and 4.0 mol% CuI in degassed tetrahydrofuran. Triethylamine is charged at 3.0 eq as both base and co-solvent, and the heterogeneous mixture is agitated at 250 rpm while the jacket temperature is ramped to 55–60 °C over 45 min. A modest exotherm of ΔT=8–12 °C is observed during palladium activation; the process is controlled by splitting the alkyne addition into three portions. Conversion surpasses 95% within 6–8 h, after which the crude solution is cooled, filtered through a Celite® pad to remove inorganic salts, and concentrated under reduced pressure at ≤35 °C bath temperature. The resulting brown oil is dissolved in ethyl acetate, washed with 5 wt% aqueous ammonium chloride, and treated with 3 wt% 3-mercaptopropyl-functionalised silica gel (Si-TMT equivalent) relative to crude mass for 2 h at 20–25 °C to scavenge residual copper and palladium. ICP-MS analysis of the isolated product after silica-gel chromatography typically returns Pd <5 ppm and Cu <15 ppm, values that meet the parenteral-excipient guideline limits of ICH Q3D Guideline for Elemental Impurities. The terminal alkyne-coupled product is a key intermediate en route to a series of JAK1-selective inhibitors where the (S)-pyrrolidine-2-yl substituent contributes to ATP-binding site selectivity; the process has demonstrated a reproducible isolated yield of 78–83% with chiral HPLC confirming no detectable enantiomer erosion.

What Are the Critical Process Parameters for Maintaining Chiral Integrity During Boc Removal and Subsequent Sulfonylation?

Deprotection of the tert-butyl carbamate is carried out with anhydrous 4 M HCl in 1,4-dioxane at a controlled internal temperature of 10–15 °C. The iodoimidazole-pyrrolidine substrate is dissolved in dichloromethane (6 volumes) and the acid solution is added dropwise at a rate that prevents the reaction mass from exceeding 18 °C. A detailed kinetic study using in-situ ReactIR showed that the Boc-cleavage half-life is 4.2 min at 15 °C but drops to 0.9 min at 25 °C; however, the higher-temperature condition generates 0.8–1.2 area% of the (R)-enantiomer through an acid-catalysed ring-opening/recyclisation pathway. After 2 h of ageing, the deprotected amine hydrochloride is precipitated by addition of methyl tert-butyl ether, filtered under nitrogen, and dried in a vacuum oven at 30 °C and 50 mbar for 12 h. Chiral purity of the isolated salt must exceed 99.5% ee as verified by a validated normal-phase chiral HPLC method using a Chiralpak® IA column and a hexane/ethanol/trifluoroacetic acid mobile phase, with wavelength detection at 254 nm.

The free amine is liberated immediately before sulfonylation by partitioning between dichloromethane and 2.0 eq of aqueous sodium bicarbonate. To a 0.2 M solution of the free base in dichloromethane at 0–5 °C, methanesulfonyl chloride (1.05 eq) is added via syringe pump over 30 min in the presence of 1.2 eq of N,N-diisopropylethylamine. The reaction is quenched with 1 M hydrochloric acid after 1 h, and the organic layer is repeatedly washed with water until conductivity drops below 50 μS·cm⁻¹. Concentration and crystallisation from ethyl acetate/n-heptane (1:4 v/v) affords a white crystalline methanesulfonamide with an isolated yield of 87–92% and a melting point of 158–160 °C. This sulfonamide building block has been incorporated into histamine H3 receptor antagonist leads, where the (S)-configuration is retained throughout the remaining synthetic steps, confirmed by comparative X-ray crystallography of the final active pharmaceutical ingredient. Residual solvent analysis per USP <467> showed ethyl acetate <400 ppm, n-heptane <300 ppm, and dichloromethane <30 ppm, satisfying ICH Q3C limits.

Suzuki-Miyaura cross-coupling of the 5-iodoimidazole with arylboronic acids is performed in a degassed mixture of 1,4-dioxane and deionised water (4:1 v/v) at a substrate concentration of 0.15 M. The catalytic system consists of 1.5 mol% Pd(dppf)Cl₂·CH₂Cl₂ and 2.5 eq of potassium carbonate acting as a mild base compatible with the Boc-protecting group. The boronic acid partner is charged as a 1.25 eq portion because stoichiometric excess is necessary to compensate for competitive protodeboronation; kinetic profiling via ¹¹B NMR revealed 8–12% of the boronic acid hydrolyses to the corresponding arene within the first 15 min of heating to 85 °C. The biphasic reaction mixture is stirred vigorously at 500–600 rpm to maintain adequate interfacial contact, with a blade-tip speed of 1.8 m·s⁻¹ in a 30 L oil-heated reactor. After 5–7 h, HPLC analysis indicates ≤2.0 area% of starting iodide remaining. The cooled mixture is diluted with ethyl acetate and passed through a pad of Celite® and activated charcoal to reduce palladium content prior to aqueous work-up.

The crude Suzuki product is purified by flash chromatography using a gradient of ethyl acetate in heptane, and the pooled fractions are concentrated under vacuum below 40 °C. The isolated solid exhibits a purity exceeding 98.5% by HPLC at 254 nm and an enantiomeric excess identical to the input starting material, confirming that the Pd(dppf)Cl₂ catalytic cycle does not interfere with the chiral centre. This biaryl intermediate is subsequently advanced to substituted imidazole-containing compounds evaluated as selective kinase insert domain receptor inhibitors; the palladium scavenging step using Si-TMT (3 wt%) is repeated until the palladium content measured by ICP-MS stays under the 10 ppm threshold specified in the project’s internal quality agreement. A secondary orthogonal technique, graphite furnace atomic absorption spectroscopy, is employed as a confirmatory method every five batches.

A 5-Iodoimidazole Building Block in Negishi Alkyl Side-Chain Elaboration

Alkylzinc reagents are generated from the corresponding alkyl bromides using 1.2 eq of Rieke® zinc activated by 2 mol% of 1,2-dibromoethane and trimethylsilyl chloride in N,N-dimethylacetamide at 50 °C. The resulting dialkylzinc solution is titrated with stoichiometric iodine before coupling. The iodoimidazole substrate is added as a 1.0 M stock in tetrahydrofuran, and a 1.0 mol% Pd(OAc)₂ / 2.0 mol% 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl ligand system is employed to minimise β-hydride elimination. The Negishi coupling proceeds smoothly at ambient temperature initially, requiring a controlled ramp to 50 °C over 1 h to reach full conversion. However, batch-to-batch variability in zinc activation has been observed when relative humidity in the glovebox exceeds 30%; therefore, organozinc preparation is conducted exclusively under nitrogen inertisation with a dew point below −50 °C. The final product, carrying an alkyl chain at the imidazole 5-position, is deprotected and elaborated into a series of CNS-penetrant enzymatic inhibitors. Typical isolated yields in a kilo-laboratory setting range between 55% and 62%, a reflection of the moderate stability of the imidazole-zinc intermediate in the aqueous quench step.

Beyond carbon-carbon bond-forming processes, the iodine atom permits Ullmann-type C–N coupling when heated with imidazole itself and 10 mol% copper(I) iodide in the presence of 20 mol% trans-N,N′-dimethylcyclohexane-1,2-diamine as ligand. The reaction is carried out in a pressure tube at 110 °C with potassium carbonate as base, and after 24 h the N-arylated product is recovered in 45–55% yield after column chromatography. This transformation is sensitive to trace water, which depresses the effective ligand concentration and promotes hydrolysis of the Boc group to a pyrrolidine free base that irreversibly coordinates to copper. Consequently, molecular sieves (3 Å) are pre-dried at 300 °C for 4 h and added as 50 wt% of the substrate mass immediately before sealing the reaction vessel. The resulting bis-imidazole intermediate serves as a ligand precursor for asymmetric catalysis, and its elemental purity specification requires copper content below 20 ppm as per ICH Q3D.

The ability to establish a documented elemental impurity clearance strategy has become a de facto gate check for international buyers sourcing advanced intermediates for late-phase clinical trials. Every commercial shipment of this iodoimidazole-derived product is supported by a comprehensive heavy-metal scavenging report specifying the amount and type of metal scavenger resin used, the bed volumes of the filtration set-up, and the flow rate expressed in bed volumes per hour. For a 25 kg campaign, a 10 cm diameter column packed with 5 kg of functionalised silica (thiol loading 1.2 mmol·g⁻¹) efficiently achieves effluent Pd below 2 ppm and Cu below 5 ppm when the crude product solution is percolated at 0.5 BV·h⁻¹. Breakthrough curves are monitored by collecting fractions every 0.5 BV and subjecting them to online X-ray fluorescence screening, a practice that aligns with the process analytical technology expectations described in ICH Q8(R2).

Audit-trail review from an eight-batch campaign highlighted that palladium content typically plateaus at 0.5–1.5 ppm after 10 BV of flushing when the initial palladium charge is kept below 50 ppm in the crude feed. However, if a higher catalyst loading of 3.0 mol% was employed due to a sluggish coupling, the scavenger column requires repacking after 6 BV to maintain breakthrough below the alert limit. These operational boundaries underscore why the supplier’s process development report must include a design space justification that maps palladium feed concentration against scavenger bed volume under ICH Q11 guidelines. Access to this level of process characterisation data has become a prerequisite for European and North American contract manufacturing organisations that file Drug Master Files and perform reaction-hazard assessments in accordance with ECHA Guidance on the preparation of registration dossiers.

Published data for enzymatic kinetic resolutions using this exact scaffold is limited, yet the (S)-configuration is consistently preserved when downstream transformations are run below the ceiling temperature identified for racemisation. A thermogravimetric analysis coupled with chiral stability assays determined that the neat solid undergoes enantiomeric degradation only above 115 °C, measured as a 2.3% drop in ee after 30 min isothermal hold. Therefore, the recommended short-term storage condition is 2–8 °C in sealed amber glass under argon, with a retest period of 12 months when stored below 25 °C. Any deviation beyond these conditions, particularly exposure to relative humidity above 60%, must be documented through a formal out-of-specification investigation, as moisture uptake accelerates Boc-group hydrolysis and iodine displacement. The iodoimidazole-derived platform continues to be integrated into medicinal chemistry campaigns aiming at covalent reversible inhibitors of cysteine proteases, where the imidazole ring mimics histidine backbone interactions and the pyrrolidine nitrogen facilitates hydrogen bonding within the prime site pocket.